Direct quantitative detection for cell-free miR-155 in urine: A potential role in diagnosis and prognosis for non-muscle invasive bladder cancer

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3255-3266

  Zhang, Xin ^a   Zhang, Yanli ^b   Liu, Xinfeng ^b   Fang, Aiju ^b   Wang, Jinfeng ^a   Yang, Yongmei ^a   Wang, Lili ^a   Du, Lutao ^a   Wang, Chuanxin ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Biomarker; Cell free; MiR 155; Non muscle invasive bladder cancer; Urine

Indexed keywords

BIOLOGICAL MARKER; MICRORNA 155; MICRORNA; MIRN155 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CYSTECTOMY; DIAGNOSTIC TEST ACCURACY STUDY; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PILOT STUDY; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; TUMOR VOLUME; URINE CYTOLOGY; URINE LEVEL; VALIDATION STUDY; VERY ELDERLY; BLADDER; BLADDER TUMOR; CYSTITIS; DISEASE COURSE; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR RECURRENCE; URINE;

ADULT; AGED; BIOMARKERS, TUMOR; CYSTITIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84962311560     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6487     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J and Roupret M. EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder: update 2013. European urology. 2013; 64:639-653.
3. Witjes JA and Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. European urology. 2008; 53:45-52.
4. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Drager BJ, Schalken JA, Fradet Y, Marberger M, Messing E and Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005; 66:35-63.
5. Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M. microRNAs in cancer management. The lancet oncology. 2012; 13:e249-258.
6. Kosaka N, Iguchi H and Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer science. 2010; 101:2087-2092.
7. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ and Wang K. The microRNA spectrum in 12 body fluids. Clinical chemistry. 2010; 56:1733-1741.
8. Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, Hamdy FC and Catto JW. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. British journal of cancer. 2012; 107:123-128.
9. Mengual L, Lozano JJ, Ingelmo-Torres M, Gazquez C, Ribal MJ and Alcaraz A. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. International journal of cancer. 2013; 133:2631-2641.
10. Faraoni I, Antonetti FR, Cardone J and Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochimica et biophysica acta. 2009; 1792:497-505.
11. Yim RL, Wong KY, Kwong YL, Loong F, Leung CY, Chu R, Lam WW, Hui PK, Lai R and Chim CS. Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas. Oncotarget. 2014; 5:9770-9782. doi: 10.18632/oncotarget.2390.
12. Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, Cai H, Fu D, Fan Y and Lv Z. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/beta-catenin signaling. The Journal of clinical endocrinology and metabolism. 2013; 98:E1305-1313.
13. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X and Sun S. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology. 2012; 56:1631-1640.
14. Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y and Du J. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2013; 49:604-615.
15. Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL and Huebner K. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014; 5:1174-1184. doi: 10.18632/oncotarget.1682.
16. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3:32-35.
17. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, Yoshino H, Kawahara K, Nishiyama K, Seki N and Nakagawa M. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer science. 2011; 102:522-529.
18. Wang G, Tam LS, Kwan BC, Li EK, Chow KM, Luk CC, Li PK and Szeto CC. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clinical rheumatology. 2012; 31:435-440.
19. Wang G, Tam LS, Li EK, Kwan BC, Chow KM, Luk CC, Li PK and Szeto CC. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. The Journal of rheumatology. 2010; 37:2516-2522.
20. Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC and Ng CF. Expression of microRNAs in the urine of patients with bladder cancer. Clinical genitourinary cancer. 2012; 10:106-113.
21. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE and Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clinical chemistry. 2011; 57:84-91.
22. Ono S, Oyama T, Lam S, Chong K, Foshag LJ and Hoon DS. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015; 6:7053-7064. doi: 10.18632/oncotarget.3142.
23. Zhang X, Yang X, Zhang Y, Liu X, Zheng G, Yang Y, Wang L, Du L and Wang C. Direct serum assay for cellfree bmi-1 mRNA and its potential diagnostic and prognostic value for colorectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015; 21:1225-1233.
24. Rayner KJ and Hennessy EJ. Extracellular communication via microRNA: lipid particles have a new message. Journal of lipid research. 2013; 54:1174-1181.
25. Gallo A, Tandon M, Alevizos I and Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PloS one. 2012; 7:e30679.
26. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF and Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:5003-5008.
27. Wang H and Men CP. Correlation of Increased Expression of MicroRNA-155 in Bladder Cancer and Prognosis. Laboratory medicine. 2015; 46:118-122.
28. Peng Y, Dong W, Lin TX, Zhong GZ, Liao B, Wang B, Gu P, Huang L, Xie Y, Lu FD, Chen X, Xie WB, He W, Wu SX and Huang J. MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. Oncotarget. 2015; 30:16043-16058. doi: 10.18632/oncotarget.3755.
29. Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, Creighton CJ, Anderson ML, Lazar AJ, Calin GG, Pollock RE and Lev D. miR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer research. 2012; 72:1751-1762.
30. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY and Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014; 33:679-689.
31. Huang X, Shen Y, Liu M, Bi C, Jiang C, Iqbal J, McKeithan TW, Chan WC, Ding SJ and Fu K. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. The American journal of pathology. 2012; 181:26-33.
32. Liu WJ, Zhao YP, Zhang TP, Zhou L, Cui QC, Zhou WX, You L, Chen G and Shu H. MLH1 as a direct target of MiR-155 and a potential predictor of favorable prognosis in pancreatic cancer. J Gastrointest Surg. 2013; 17:1399-1405.
33. Eissa S, Swellam M, El-Khouly IM, Kassim SK, Shehata H, Mansour A, Esmat M, Nossier AI, Hamdy MA, Awad NM and El-Ahmady O. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20:1657-1664.
34. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S and Kuwano M. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer research. 2002; 62:4048-4053.
35. Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP and Wu X. Genetic variations of the PI3K-AKTmTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 2010; 31:1387-1391.
36. Abbosh PH, Wang M, Eble JN, Lopez-Beltran A, Maclennan GT, Montironi R, Zheng S, Pan CX, Zhou H and Cheng L. Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. Mod Pathol. 2008; 21:355-362.
37. Lind EF and Ohashi PS. MiR-155, a central modulator of T-cell responses. European journal of immunology. 2014; 44:11-15.
38. O'Connell RM, Taganov KD, Boldin MP, Cheng G and Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:1604-1609.
39. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S and Croce CM. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:4908-4913.
40. Schmitz-Drager BJ, Todenhofer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M and Kamat A. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urologic oncology. 2014; 32:1061-1068.
41. Jin X, Yun SJ, Jeong P, Kim IY, Kim WJ and Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget. 2014; 5:1635-1645. doi: 10.18632/oncotarget.1744.
42. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Roupret M, Shariat SF and Zlotta AR. Urine markers for detection and surveillance of nonmuscle-invasive bladder cancer. European urology. 2011; 60:484-492.
43. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, Sun Q, Wang K, Ba Y, Wang Q, Wang D, Yang J, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Molecular cell. 2010; 39:133-144.
44. Xu J, Chen Q, Zen K, Zhang C and Zhang Q. Synaptosomes secrete and uptake functionally active microRNAs via exocytosis and endocytosis pathways. Journal of neurochemistry. 2013; 124:15-25.
45. Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, Wang X, Liu Y, Xu N, Yan X and Guo H. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget. 2015; 6:8914-8928. doi: 10.18632/oncotarget.3563
46. DeLong ER, DeLong DM and Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44:837-845.